Testing an injection therapy for stubborn ringworm infections
Part of Infections, Skin clinical trials.
This study tests a new type of injection treatment for stubborn ringworm (tinea) infections that haven't improved with standard pills or creams. It aims to see if this immunotherapy works better for hard-to-treat cases, especially when the fungus might be resistant to usual medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 60 years old.
- You have ringworm that did not get better after at least two different prescription antifungal treatments in the last 3 months.
- The infection is spreading fast, covers large areas, or keeps coming back. (Or someone else in your home, especially a woman or child, also has ringworm.)
- If you are a woman who could become pregnant, you must agree to use reliable birth control during the study.
- You are not pregnant or breastfeeding, and you do not have a condition that weakens your immune system (like uncontrolled diabetes or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a second medication, isotretinoin, to the standard itraconazole treatment works faster or better for adults with ringworm on their body. It aims to find a safer and more effective way to treat this common fungal skin infection.
This trial compares two oral medications, fluconazole and itraconazole, to see which works better for treating ringworm that hasn't cleared up with topical creams. If you've had ringworm for at least 6 months despite using antifungal creams, this study may help find a more effective treatment.
This trial tests a stronger antifungal pill, voriconazole, for people whose ringworm (a fungal skin infection) hasn't cleared up after other treatments. It focuses on infections on the groin or trunk.
This trial tests if ultraviolet B (UVB) phototherapy can treat ringworm infections that have not improved with standard antifungal pills or have come back multiple times. It may be an option if you still have symptoms after taking terbinafine or itraconazole for at least 4 weeks.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
Hear when a new Tinea Corporis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.